Skip to content
value.today

Recro Pharma, Inc.

Total raised
$16 M
1 round on record
Latest round
$16 M
Jul 2015
First round on record
Jul 2015
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Recro Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2015$16 MNo. 1$10 to $50 million

Recro Pharma, Inc.: Raise no. 1, Jul 2015

Investors in this round

3 investors had bought by the notice of Jul 13, 2015: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Recro Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$960,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Pennsylvania

People named in the notice

  • Charles A Garner · Executive Officer
  • Donna A Nichols · Executive Officer
  • Gerri A Henwood · Executive Officer, Director
  • Abraham J Ludomirski · Director
  • Alfred A Altomari · Director
  • Michael L Berelowitz · Director
  • Wayne B Weisman · Director
  • William L Ashton · Director
  • Winston J Churchill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MLV & Co. LLC (CRD 150959) · New York, New YorkSold in all US states
  • Janney Montgomery Scott LLC (CRD 463) · Philadelphia, PennsylvaniaSold in all US states
  • Jefferies LLC (CRD 2347) · New York, New YorkSold in all US states
  • Brean Capital, LLC (CRD 23723) · New York, New YorkSold in all US states

Signed by Gerri A. Henwood, President & CEO. Source: SEC Form D, newest notice filed Jul 13, 2015. Read the notice at the SEC.

equitySEC
Apr 2015$8 MIssued in a merger or acquisition$2 to $10 million

Recro Pharma, Inc.: Private sale, Apr 2015

Investors in this round

2 investors had bought by the notice of Apr 23, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Recro Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Pennsylvania

People named in the notice

  • Gerri A. Henwood · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Warrants were issued in connection with the Company's purchase of certain subsidiaries of Alkermes plc pursuant to a Purchase and Sale Agreement. See the Company's Form 8-K filed on April 15, 2015.”

Signed by Gerri A. Henwood, President & CEO. Source: SEC Form D, newest notice filed Apr 23, 2015. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Recro Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2015).

    SEC Form D · Jul 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2015

That is all the official record says: Recro Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Recro Pharma, Inc.
InvestorKindAmountRoundRoleSource
SCP Vitalife Partners II LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2014)SEC Form 3
SCP Vitalife Partners (Israel) II, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 3 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Recro Pharma, Inc.
NameRoleNamed in
Charles A GarnerExecutive officerJul 2015
Donna A NicholsExecutive officerJul 2015
Gerri A HenwoodExecutive officerJul 2015
Gerri A. HenwoodExecutive officerApr 2015
Abraham J LudomirskiDirectorJul 2015
Alfred A AltomariDirectorJul 2015
Gerri A HenwoodDirectorJul 2015
Michael L BerelowitzDirectorJul 2015
Wayne B WeismanDirectorJul 2015
William L AshtonDirectorJul 2015
Winston J ChurchillDirectorJul 2015